Coalition for North American Drug Supply Calls for Urgent Action Amidst Reports of Contaminated Eye Drops from India

Saint Charles, Illinois Nov 15, 2023 (Issuewire.com) - Recent investigations reported by Morningstar and the New York Post have unveiled alarming lapses in safety and quality control at a pharmaceutical manufacturing facility in India. The Coalition for North American Drug Supply is calling for immediate action to address the issue and advocating for the relocation of drug production to the United States and Canada.

Key Points:

• Ensuring Safety and Quality: Recent incidents underscore the potential risks associated with overseas drug production. The Coalition advocates for localizing drug manufacturing to uphold the highest safety and quality standards.

• Protecting Public Health: Reports from both Morningstar and the New York Post highlight serious safety and quality concerns related to contaminated eye drops found at major retailers. The Coalition stresses the urgency of addressing these issues to safeguard public health.

• Barefoot Workers and Faked Safety Checks: The New York Post's report brings attention to the shocking revelation of workers in India going barefoot during drug manufacturing and falsifying safety checks. Such practices raise significant doubts about the integrity of the global pharmaceutical supply chain.

• Immediate Action Required: The Coalition urges immediate action to address the contamination issue and investigate the conditions under which these drugs were manufactured. The health and safety of consumers are of paramount importance.

• Supply Chain Vulnerabilities: The recent incidents highlight the vulnerability of the global pharmaceutical supply chain. Localizing drug production in North America is crucial to mitigating such risks and ensuring the integrity of medicines.

• Transparent Oversight: The Coalition calls for increased transparency and oversight in the pharmaceutical industry. We believe that transparency is vital for building trust among consumers and stakeholders.

• Creating Jobs: Bringing drug production back to North America will contribute to the growth of local economies by generating employment opportunities and supporting skilled workers in the pharmaceutical industry.

• Enhancing Regulatory Oversight: In response to these revelations, the Coalition urges immediate regulatory reforms to ensure transparency, oversight, and continuous monitoring of pharmaceutical manufacturing processes.

• Collaboration Across Borders: The Coalition encourages collaboration between the United States and Canada to develop a comprehensive strategy for localizing drug production and safeguarding the health of North American citizens.

The Coalition for North American Drug Supply remains steadfast in its commitment to advocating for a secure and reliable drug supply chain. By bringing drug production back to North America, we aim to protect public health, create jobs, and ensure the highest standards of safety and quality.

For media inquiries, please contact:

Mr. Samay Verma

President

646-780-9916

https://www.cnads.org/

https://www.paypal.com/donate/?hosted_button_id=WT9Y9V9AEZHQ8

Media Contact

Coalition For North American Drug Supply Inc.

[email protected]

646-780-9916

http://cnads.org